France
· Delayed Price · Currency is EUR Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of EUR 169.19 million. The enterprise value is 116.62 million.
| Market Cap | 169.19M |
| Enterprise Value | 116.62M |
Important Dates
The next estimated earnings date is Thursday, September 12, 2024.
| Earnings Date | Sep 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 80.95 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Shares Outstanding | 80.95M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 2.48% |
| Owned by Institutions (%) | 2.01% |
| Float | 31.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.73 |
| PB Ratio | 3.26 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.41 |
| EV / Sales | 1.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.54 |
Financial Position
The company has a current ratio of 3.73, with a Debt / Equity ratio of 76.86.
| Current Ratio | 3.73 |
| Quick Ratio | 3.51 |
| Debt / Equity | 76.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.21 |
| Interest Coverage | -19.80 |
Financial Efficiency
Return on equity (ROE) is -14.28% and return on invested capital (ROIC) is -8.41%.
| Return on Equity (ROE) | -14.28% |
| Return on Assets (ROA) | -4.04% |
| Return on Capital (ROIC) | -8.41% |
| Revenue Per Employee | 344,363 |
| Profits Per Employee | -42,291 |
| Employee Count | 179 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.67% in the last 52 weeks. The beta is 0.81, so Innate Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -26.67% |
| 50-Day Moving Average | 2.04 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 53.47 |
| Average Volume (20 Days) | 25,829 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innate Pharma had revenue of EUR 61.64 million and -7.57 million in losses. Loss per share was -0.09.
| Revenue | 61.64M |
| Gross Profit | 5.62M |
| Operating Income | -12.67M |
| Pretax Income | -7.57M |
| Net Income | -7.57M |
| EBITDA | -7.58M |
| EBIT | -12.67M |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 92.46 million in cash and 39.89 million in debt, giving a net cash position of 52.56 million or 0.65 per share.
| Cash & Cash Equivalents | 92.46M |
| Total Debt | 39.89M |
| Net Cash | 52.56M |
| Net Cash Per Share | 0.65 |
| Equity (Book Value) | 51.90M |
| Book Value Per Share | 0.64 |
| Working Capital | 108.38M |
Cash Flow
In the last 12 months, operating cash flow was -32.56 million and capital expenditures -351,000, giving a free cash flow of -32.91 million.
| Operating Cash Flow | -32.56M |
| Capital Expenditures | -351,000 |
| Free Cash Flow | -32.91M |
| FCF Per Share | -0.41 |
Margins
Gross margin is 9.12%, with operating and profit margins of -20.55% and -12.28%.
| Gross Margin | 9.12% |
| Operating Margin | -20.55% |
| Pretax Margin | -12.28% |
| Profit Margin | -12.28% |
| EBITDA Margin | -12.29% |
| EBIT Margin | -20.55% |
| FCF Margin | -53.39% |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | -4.50% |
| FCF Yield | -19.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |